Get the Stockscreener App
53.11
0.30%
-0.16
Travere Therapeutics Inc stock is traded at $53.11, with a volume of 985.73K.
It is down -0.30% in the last 24 hours and down -15.04% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
See More
Previous Close:
$53.27
Open:
$53.94
24h Volume:
985.73K
Relative Volume:
0.46
Market Cap:
$5.01B
Revenue:
$536.20M
Net Income/Loss:
$-45.64M
P/E Ratio:
-99.31
EPS:
-0.5348
Net Cash Flow:
$-28.94M
1W Performance:
+2.06%
1M Performance:
-15.04%
6M Performance:
+29.69%
1Y Performance:
+97.80%
1-Day Range:
$53.09
$55.57
1-Week Range:
$51.38
$53.94
52-Week Range:
$22.59
$68.73
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
53.11 | 5.01B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.91 | 82.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
847.02 | 53.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-31-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics CLO Elizabeth Reed sells $2.34m in stock By Investing.com - Investing.com Nigeria
Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock - Investing.com
Travere Therapeutics CFO Cline sells $3.1m in company stock - Investing.com
Travere Therapeutics SVP sells $335k in stock - Investing.com
Travere Therapeutics SVP sells $335k in stock By Investing.com - Investing.com Canada
Travere (TVTX) R&D boss sells stock under 10b5-1 plan—how big was the trade? - Stock Titan
Insider at Travere (NASDAQ: TVTX) sells stock under preset trading plan - Stock Titan
Travere Therapeutics (TVTX) legal chief sells 37,500 shares under trading plan - Stock Titan
Travere CFO (NASDAQ: TVTX) sells 50K shares in pre-set trading plan - Stock Titan
Travere Therapeutics (TVTX) CEO trades 400K shares under preset plan - Stock Titan
Travere Therapeutics (TVTX) research chief unloads shares under a preset plan, with the sale size now disclosed - Stock Titan
Planned $6.9M stock sale in Travere (NASDAQ: TVTX) - Stock Titan
Travere Therapeutics, Inc.Common Stock (Nasdaq:TVTX) Price Chart - The Chronicle-Journal
Travere Therapeutics (TVTX) chief accounting officer sells 5,375 shares under preset plan - Stock Titan
Travere (NASDAQ: TVTX) insider plans more stock sales after multi-million plan trades - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) officer plans 112,850-share sale after recent 96,198-share trade - Stock Titan
After $6M sale, Travere (NASDAQ: TVTX) insider plans another stock move - Stock Titan
Travere Therapeutics (TVTX) insider plans 172,717-share sale after option exercise - Stock Titan
Insider plans 39,576-share sale at Travere Therapeutics (NASDAQ: TVTX) in 2026 - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) shareholder Eric Dube plans 95,666-share sale in September 2026 - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) officer may sell shares after cashing in options - Stock Titan
$2.9M planned stock sale at Travere (NASDAQ: TVTX) comes from equity awards - Stock Titan
Over 100,000 Travere (NASDAQ: TVTX) shares lined up for insider sale - Stock Titan
Travere Therapeutics (NASDAQ: TVTX) officer plans Rule 144 sale of compensation shares - Stock Titan
TVTX Form 4 FilingsTravere Therapeutics, Inc. SEC Form 4 - Stock Titan
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Director at Travere Therapeutics (TVTX) sells 20,000 shares under preset trading plan - Stock Titan
Show Me The Money: Filspari Powers Travere Therapeutics' Growth - RTTNews
Travere Therapeutics grants inducement RSUs covering 56,220 shares to 16 new employees - Bitget
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Australia
Travere Therapeutics (NASDAQ: TVTX) director plans 2026 stock sale - Stock Titan
TVTX: FILSPARI's momentum and pipeline progress position the business for sustained growth - TradingView
Travere Therapeutics at Cantor conference: filspari drives growth By Investing.com - Investing.com Canada
Travere Therapeutics at Cantor conference: filspari drives growth By Investing.com - Investing.com UK
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Nigeria
Travere Therapeutics stock hits 52-week high at 68.25 USD - investing.com
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com Canada
Travere Therapeutics stock hits 52-week high at 68.25 USD By Investing.com - Investing.com UK
Travere Therapeutics' Outlook Brightens As Turnaround Looms - Investor's Business Daily
FDA issues Untitled Letter to Travere Therapeutics over visual aid for kidney disease drug Filspari - Medical Marketing and Media
Seong Chi: Excited to Join Travere Therapeutics as Director, Scientific Engagement and Professional Societies - Oncodaily
Biotech Stocks At 52-Week HighsATTO, HALO, IKT, TVTX, ATRC - RTTNews
Travere Therapeutics CFO Christopher R. Cline Executes 642-Share Sale for Tax Withholding on RSU Vesting - Kalkine Media
Travere Therapeutics stock hits 52-week high at 67.97 USD By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 67.97 USD By Investing.com - Investing.com South Africa
Travere Therapeutics stock hits 52-week high at 67.97 USD By Investing.com - Investing.com India
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Travere Therapeutics Inc Stock (TVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ERIC DUBE | Director |
Sep 17 '26 |
Proposed Sale |
63.48 |
108,493 |
6,887,136 |
0 |
| PETER HEERMA | Officer |
Sep 17 '26 |
Proposed Sale |
63.48 |
8,282 |
525,741 |
0 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Sep 17 '26 |
Option Exercise |
23.34 |
108,493 |
2,532,227 |
541,379 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 17 '26 |
Option Exercise |
22.40 |
8,282 |
185,517 |
125,348 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Sep 17 '26 |
Sale |
64.61 |
108,493 |
7,009,671 |
432,886 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 17 '26 |
Sale |
65.07 |
8,282 |
538,917 |
117,066 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 16 '26 |
Option Exercise |
14.19 |
172,717 |
2,451,533 |
289,783 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER |
Sep 16 '26 |
Sale |
63.43 |
172,717 |
10,956,088 |
117,066 |
| PETER HEERMA | Officer |
Sep 16 '26 |
Proposed Sale |
62.51 |
172,717 |
10,796,540 |
0 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Sep 16 '26 |
Sale |
63.45 |
195,841 |
12,425,254 |
432,886 |
2.44%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):